Flucef

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flucef

Property Description
Active ingredient Flucloxacillin (often as Flucloxacillin sodium)
Form Capsule, Tablet, Oral liquid, Powder for injection
Pharmacological class Semi-synthetic Penicillin Antibiotic (beta-Lactam)
General purpose Elimination of susceptible bacterial infections
Origin Semi-synthetic

Flucef: Definition, Classification, and Origin

Flucef is a prescription antibiotic medicine containing the active ingredient Flucloxacillin, which is utilized to fight bacterial infections in the body. This medication belongs to the pharmacological class of isoxazolyl penicillins, a category of beta-lactam antibiotics. Flucloxacillin is defined as a semi-synthetic derivative, meaning it is partially manufactured from the natural penicillin structure. It is specifically characterized as a beta-lactamase stable penicillin because its unique structure prevents its destruction by the bacterial enzyme beta-lactamase, which certain bacteria produce to achieve resistance. This feature is clinically recognized for its reliability in managing related infections, ensuring the antibiotic remains active against susceptible strains, such as penicillinase-producing Staphylococcus species.

Forms, Composition, and General Purpose

The drug’s general purpose is to act as a bactericidal anti-infective agent, eliminating susceptible bacteria responsible for infections within the body. Flucef, or medicines containing Flucloxacillin, are supplied as a single active ingredient product in various pharmaceutical preparations, enabling delivery via different routes of administration. These preparations include solid dosage forms, such as capsules and tablets for oral ingestion, as well as powder for injection provided in vials for parenteral (intravenous or intramuscular) administration. The availability of these distinct forms ensures that Flucloxacillin can be administered appropriately to combat common conditions, such as skin and soft tissue infections, which represents a typical use scenario for this specific antibiotic class. Ultimately, this action helps the body achieve resolution of the underlying bacterial infection.

What side effects are possible with Flucef?

The safety profile of Flucef is established through clinical trials and post-marketing surveillance, detailing common reactions, serious warnings, and specific limitations.

Serious Warnings and Clinically Significant Adverse Reactions

The United States Food and Drug Administration (FDA) label includes a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants. Serious and potentially life-threatening reactions reported with Flucef use include Serotonin Syndrome, Abnormal Bleeding (including gastrointestinal), Seizures, Activation of Mania/Hypomania, and QT Prolongation with associated ventricular arrhythmia, including Torsades de Pointes. Other risks include Hyponatremia (low blood sodium levels) and Angle-Closure Glaucoma.

Common Side Effects and Affected Systems

Adverse reactions reported in clinical trials that occurred at an incidence of 5% or more and at least twice the placebo rate are classified as common. These frequently reported events involve the nervous, gastrointestinal, and psychiatric systems. Examples include nausea, insomnia, diarrhea, headache, anxiety, nervousness, asthenia (weakness), tremor, dry mouth, and decreased libido.

Safety Restrictions and Population Considerations

Flucef is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of Serotonin Syndrome, and with Pimozide or Thioridazine due to the risk of cardiac effects. Caution is advised in patients with a history of seizures or risk factors for QT prolongation. Dose adjustments are typically necessary for patients with hepatic impairment. Use of SSRIs late in pregnancy may be associated with increased risk for persistent pulmonary hypertension and symptoms of poor adaptation in the neonate. Following treatment cessation, symptoms such as dizziness and paresthesia may occur, known as discontinuation adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

This information reflects the documented overdose profile as defined by regulatory health authorities.

Overdose with Flucef (a representative SSRI) may present with a range of symptoms, primarily affecting the Central Nervous System (CNS) and Cardiovascular system. Documented manifestations often include drowsiness, tremor, agitation, nausea, vomiting, and sinus tachycardia (rapid heart rate).


Serious Outcomes and Emergency Action

Overdose can lead to potentially life-threatening outcomes, including seizures, QTc prolongation (a serious heart rhythm abnormality), and Serotonin Syndrome. Serotonin Syndrome is a critical condition characterized by neuromuscular changes and autonomic instability.

Emergency Action Required Regulatory Statement
Immediate Medical Help Urgent medical attention is required for severe symptoms such as collapse, difficulty breathing, or seizure.
Antidote Status No specific antidote is available or listed in official documents.

Overdose Management

Management is supportive and symptomatic. Following exposure, close monitoring of cardiac function (e.g., ECG) and vital signs is necessary. Procedures like gastric decontamination (e.g., activated charcoal) may be considered by medical professionals based on the time and amount of ingestion. Patients with underlying conditions, particularly hepatic or cardiac issues, may require specialized monitoring.

Therapeutic Uses of Flucef

The primary role of Flucef (Flucloxacillin) is its application in areas where additional symptomatic support is needed to manage infections caused by susceptible bacteria, and it is relevant in certain infectious contexts. Its therapeutic relevance is consistent with official guidance on its use, and it is commonly used across domains where increased discomfort or tension are evident. It is relevant in conditions characterized by periods of heightened symptoms, including conditions presenting with systemic or localized discomfort, such as skin and soft tissue infections, deep-seated infectious manifestations, and in specialized scenarios such as infection prophylaxis during major orthopedic surgery.

“Flucef helps address symptom clusters that may become intense or disruptive, including pronounced redness, swelling, and pain associated with inflammatory or irritative states.”

The medicine is often used during phases when symptoms become more noticeable, such as high fever and signs of systemic imbalance, providing support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable.


Quick Fact: Relief for Localized Discomfort
Flucef supports patients experiencing symptoms related to inflammatory or irritative states in the skin, contributing to easing the overall symptom load during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Flucef? - Official Regulatory Information

Regulatory documents define specific eligibility and non-eligibility criteria for using Flucef, primarily based on contraindications and patient status.


Contraindicated (Must Not Use)

Flucef is strictly contraindicated (must not be used) in patients who have a known hypersensitivity or allergy to fluoxetine or any of its components.

It must also not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs) intended to treat psychiatric disorders, requiring a specified washout period before starting or stopping either drug. Other specific drug combinations are also forbidden, including concurrent use with pimozide, thioridazine, linezolid, or intravenous methylene blue.


Age and Physiological Restrictions

Official labeling sets specific minimum age requirements for use, and the safety and effectiveness of Flucef have not been established in children below 8 years of age for Major Depressive Disorder (MDD) or below 7 years of age for Obsessive-Compulsive Disorder (OCD).

Use in pregnant individuals should only occur if the potential benefit justifies the risks, and use by nursing mothers is not recommended. Patients with pre-existing conditions like hepatic impairment (liver disease) may require special considerations, such as a lower or less frequent dosage schedule, as the body's ability to metabolize the medicine may be reduced.

What should I know about interactions with other medicines?

Flucef (Flucloxacillin) Interactions with other medicines and products are officially documented across several pharmacokinetic and pharmacodynamic domains in regulatory labeling. The co-administration of certain medicines is noted to affect drug exposure, therapeutic efficacy, or introduce specific toxicological risk.

Pharmacokinetic and Exposure Alterations

The drug is identified as altering the exposure of key medicines. Co-administration with Warfarin requires stringent monitoring of the International Normalized Ratio (INR), as Flucloxacillin may decrease the anticoagulant effect, an outcome associated with its potential to induce metabolic enzymes. Agents that inhibit renal tubular secretion, such as Probenecid and Sulfinpyrazone, result in prolonged and increased plasma concentrations of Flucloxacillin. Furthermore, the co-use with Methotrexate reduces the excretion of the cytotoxic agent, creating a documented risk of elevated exposure and toxicity. Co-administration with Voriconazole is associated with a potential loss of effectiveness of the antifungal medicine.

Specific Toxicity and Administration Rules

A specific interaction is documented with Paracetamol, where concurrent intake is associated with an increased risk of High Anion Gap Metabolic Acidosis (HAGMA). Official labeling emphasizes this risk for patients with co-existing conditions, particularly severe renal impairment, sepsis, or malnutrition. Due to documented interference with gastrointestinal absorption, the oral form of Flucloxacillin must be administered on an empty stomach, typically requiring separation from a meal by one to two hours. The drug may also interfere with the efficacy of the live oral typhoid vaccine and bacteriostatic antibiotics like Tetracyclines.

Mechanism of Action

How Flucef Works: Mechanism of Action

Selective Blockade of Serotonin Reuptake

Flucef's primary mechanism involves the selective inhibition of the Serotonin Transporter ( SERT), a protein located on pre-synaptic neuronal membranes. This interaction blocks the reabsorption of the neurotransmitter serotonin ( 5-HT), thereby increasing its concentration and duration of action within the synaptic cleft . This initial molecular change modulates the activity of serotonergic signaling in central pathways governing emotional regulation.


Long-Term Pathway Adaptation

The resulting sustained elevation of synaptic serotonin initiates a chronic, time-dependent cascade. This process involves the downregulation of specific 5-HT autoreceptors and the modulation of cellular machinery, leading to an increase in neurotrophic factors such as BDNF. These changes support neuronal plasticity, initiating signaling sequences that modify early molecular steps and promote the remodeling of neural circuits over several weeks.


System-Level Consequence

This prolonged physiological adjustment results in a sustained alteration of dynamics within targeted central pathways. The full effect emerges gradually as the nervous system adapts to the new chemical environment, establishing the physiological changes that contribute to the drug's overall effect profile.

Dosage and Administration Information

How to Use Flucef: Official Administration Guidelines

Flucloxacillin (Flucef) usage follows specific instructions mandated by regulatory bodies to ensure proper delivery and absorption. The medicine is available as oral formulations (capsules, tablets, and liquid suspension) and parenteral formulations (powder for intravenous [IV] or intramuscular [IM] injection), defining the approved routes of administration.


Standard Dosing and Frequency

The most common dosing schedule for adults and the elderly is 250 mg to 500 mg four times a day (QID), with doses administered approximately six hours apart. For severe infections, the dose may be increased, potentially reaching a maximum of 12 g daily for certain high-dose parenteral regimens. Surgical prophylaxis involves a 1 g to 2 g IV dose at the induction of anesthesia.

Feature Procedural Guideline
Timing in relation to meals Oral forms must be taken on an empty stomach—at least one hour before or two hours after food.
Renal Impairment For severe cases (CLCR < 10 mL/min), the maximum dose is restricted to 1 g every 8 to 12 hours to adjust for reduced elimination.
Parenteral Preparation Powder for injection requires reconstitution and is administered as a slow IV injection (over 3–4 minutes) or by infusion (over 30–60 minutes).
Missed Dose Rule If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; never take a double dose to compensate.

Official Use Protocol

The regulatory protocol requires adherence to these constraints, dictating the precise timing and method of delivery. The oral forms must be taken with a full glass of water, and patients should not lie down immediately afterward. The requirement for dose adjustment in renal impairment establishes a necessary modification logic based on patient physiological status, ensuring the structured use of the medicine.

Recent Clinical Evidence

Flucef: Recent Clinical Evidence

Flucef, which contains the active ingredient fluoxetine, is a medication classified as a Selective Serotonin Reuptake Inhibitor (SSRI). Its clinical use is supported by numerous randomized controlled trials and meta-analyses, primarily in the treatment of specific mental health disorders.

Established Indications and Efficacy

Clinical trial data supports the use of fluoxetine in several key areas. For adults, evidence suggests it is associated with improvement in symptoms of Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), and Bulimia Nervosa. Studies examining MDD have shown that fluoxetine was observed to be more effective than placebo in reducing depressive symptoms, often noted from the early weeks of treatment. In trials for OCD, fluoxetine demonstrated effects comparable to other standard treatments.

Safety Profile and Risk Considerations

Across multiple studies, fluoxetine has generally been characterized by its tolerability profile compared with older antidepressant classes. However, like all medications, it is associated with potential side effects. The most frequently reported adverse events include headache, insomnia, nausea, and diarrhea. Importantly, large-scale studies and registry data have highlighted specific safety signals:

  • Bone Health: Some research has indicated an increased frequency of bone fractures in patients taking fluoxetine, particularly following conditions like acute stroke.
  • Pregnancy: Use during the first trimester of pregnancy has been linked in some reports to an increased risk of specific heart defects in the newborn.
  • Suicidality Risk: Short-term trials in children, adolescents, and young adults (under 25) for MDD and other psychiatric disorders showed an elevated risk of suicidal thoughts and behaviors compared to placebo.

Ongoing Research Areas

Contemporary clinical research continues to explore the potential uses and mechanisms of fluoxetine. Studies have investigated its application in treating complications of COVID-19, with the goal of reducing the rate of hospitalization. Other exploratory research is examining its effects in rare neurological conditions and in adjunct therapies for certain brain tumors. These applications remain investigational and are not currently approved uses.

Key Studies & References

  1. Summary of Product Characteristics (Fluoxetine 20 mg/ 5 ml Oral Solution) - Health Products Regulatory Authority (HPRA)
  2. Antidepressant utilisation and risk of suicide in young people: Safety investigation - Therapeutic Goods Administration (TGA)
  3. Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review

Frequently Asked Questions (FAQ)

Common questions about Flucef (FAQ)


Q: What's the difference between Flucef and a generic version?

Official regulatory descriptions explain that a generic version of a medicine contains the exact same active ingredient as the brand-name product. Generics are required to be identical in dosage form, strength, and approved route of administration. The primary difference often relates to inactive ingredients or the manufacturer's name.


Q: How quickly should I expect Flucef to start working?

Studies and official information indicate that the full physiological effects of this medicine class emerge gradually over several weeks, as the body adapts to the medication. Early subjective effects or feeling better may become noticeable, but this can vary and is not guaranteed for every individual.


Q: Does Flucef cause weight gain or loss?

Official labeling for the SSRI class of medicine notes that some patients experience significant weight loss during treatment. The specific impact on weight for any individual is documented to vary, but changes in appetite or weight are monitored and noted in the official adverse reaction lists.


Q: Can Flucef affect sleep patterns or cause insomnia?

Yes, insomnia, which is difficulty falling asleep or staying asleep, is listed in official labeling as a frequently reported adverse reaction. This relates to the drug’s effects on the nervous system. Changes to sleep patterns, if experienced, are typically discussed with the prescribing professional.


Q: Is it normal to feel a little dizzy when starting Flucef?

Official documents list central nervous system adverse reactions such as tremor, anxiety, and nervousness for this class of medicine, which can affect a patient's alertness and coordination. Dizziness is not consistently listed as a common, standalone side effect. Central nervous system effects may occur, which is why official labeling is available for review.


Q: How long does Flucef stay in your system after stopping it?

Official pharmacokinetic descriptions for the active compound indicate it has a relatively long elimination half-life. This means the medicine and its active components can remain in the body for several weeks after the medicine has been discontinued. This characteristic is relevant to the overall period of exposure to the medicine.


Q: Does Flucef interact with common over-the-counter pain medications?

Official documents explicitly warn that combining this medicine with paracetamol (acetaminophen) is associated with an increased risk of a serious condition called high anion gap metabolic acidosis (HAGMA). This risk is noted in official warnings, particularly for individuals with certain co-existing conditions.


Q: Is it safe to drink coffee or caffeine while taking Flucef?

Regulatory guidance typically does not list coffee or caffeine as a substance that must be completely avoided. However, general patient information for the Flucloxacillin formulation advises avoiding excessive intake of caffeine. Disclosure of all consumed substances, including high-caffeine products, is part of a thorough health review.


Q: Is Flucef appropriate for elderly patients?

Official labeling addresses use in the elderly population. It indicates that lower or less frequent dosing may be appropriate for older patients or for those taking multiple medications. These adjustments account for potential differences in how the body metabolizes or eliminates the medicine.


Q: Are there any known issues with taking Flucef during pregnancy (descriptive only)?

Official labeling contains specific warnings about use during pregnancy, and risk information should be reviewed. Some reports suggest an increased risk of specific heart defects if used during the first trimester. Use late in the third trimester may also be associated with specific issues for the newborn, such as persistent pulmonary hypertension.


Q: Can Flucef be taken while breastfeeding (descriptive only)?

Official labeling confirms that use of this medicine by nursing mothers is not recommended. This guidance is given because the active compound is known to be excreted into breast milk.


Q: What happens if I miss a scheduled dose of Flucef?

Official regulatory guidance dictates that if a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official rules specify that a double dose must not be taken to compensate for a missed dose.


Q: What should I do if I accidentally take two doses of Flucef close together?

Official documents describe that symptoms may occur following an overdosage of the medicine. Due to the potential risk of serious complications, professional medical guidance is necessary, and information on signs and symptoms is listed in official documents.


Q: Does Flucef need to be taken with food, or can it be taken on an empty stomach?

The oral forms of the Flucloxacillin formulation must be taken on an empty stomach. This typically means at least one hour before or two hours after eating. This requirement exists because food can interfere with how the body absorbs the medicine, potentially reducing its effectiveness.


Q: Can Flucef be taken with vitamins or mineral supplements?

Official guidance often recommends telling a professional about all other consumed substances, including herbal remedies, vitamins, and supplements. Providing disclosure allows for a comprehensive assessment of potential interactions.


Q: Has there been much research published on the long-term effects of Flucef?

Regulatory documents confirm that clinical trial data supports the use of this medicine for specific indications. Long-term safety signals, such as potential changes to bone health, are noted in the safety profile, confirming the existence of research and surveillance into the longer-term effects of this class of drug.


Q: Why do some people report feeling tired when taking Flucef?

Official adverse reaction lists for the SSRI class of medicine include asthenia, a medical term for weakness, as a common side effect. This physical symptom may contribute to a feeling of tiredness or fatigue reported by some patients during treatment.


Q: Can Flucef be split or crushed, or must it be swallowed whole?

Official administration guidelines describe the medicine as being supplied in specific formulations like capsules and tablets, designed to be swallowed whole. Regulatory documents do not typically authorize splitting or crushing unless a specific score mark or preparation instruction is given for the product.


Q: Does Flucef affect blood pressure or heart rate?

Official warnings note a risk of QT Prolongation, which is a documented change in the electrical activity of the heart. This change can potentially affect heart rhythm. Use of this medicine is cautioned in individuals with a history of certain heart issues.


Q: Is Flucef a controlled substance?

Regulatory documents, particularly from the FDA, confirm that the active compound in Flucef is not classified as a controlled substance. This means it is not associated with significant abuse or dependence potential.


Q: Does Flucef have any known photosensitivity effects (making skin sensitive to sun)?

Official adverse reaction lists for this medicine and its class do not typically list photosensitivity, which is an increased skin sensitivity to light, as a common or frequently reported side effect.


Q: Does Flucef affect the results of common lab tests?

Official documents note that the medicine may interfere with the results of certain laboratory procedures. For example, it may affect blood coagulation tests (INR) if co-administered with certain blood thinners.


Q: Why is Flucef sometimes referred to by a different brand name?

Official drug descriptions explain that a medicine is identified by both its generic (active ingredient) name and its brand or trade name. The trade name is specific to the company that markets and sells the product, which is why a single active ingredient can have multiple brand names.


Q: How does the effectiveness of Flucef compare to a placebo in clinical trials?

Clinical trial data published in regulatory documents demonstrated that the medicine was observed to be statistically more effective than placebo. This indicates that the medicine demonstrated an effect profile that met the statistical endpoints for its established indications.


Q: What should I do if I experience unexpected mood changes while taking Flucef?

Official guidance instructs patients and caregivers to closely monitor for the worsening of symptoms or the emergence of concerning mood changes, including suicidal thoughts and behaviors. Such changes are typically reported to a healthcare professional immediately upon being noticed.


Q: Does Flucef interact with birth control pills?

Official patient information for the Flucloxacillin formulation states that it does not typically stop hormonal contraception from working. However, if the medicine causes vomiting or severe diarrhea, the effectiveness of the contraceptive pill may be reduced.


Q: Can I drive while taking Flucef?

Official patient information for the Flucloxacillin formulation states that it should not typically affect the ability to drive or cycle. However, for the SSRI class, warnings advise caution when performing tasks that require mental alertness, such as operating heavy machinery, due to the potential for adverse effects like nervousness or tremor.


Q: How is Flucef eliminated from the body?

Official pharmacokinetic documents describe the drug as being metabolized into other substances within the body. The resulting compounds are then eliminated primarily through the kidneys in the urine. This is a standard process that affects how long the medicine remains in the system.


Q: Do I need to taper off Flucef, or can I stop taking it suddenly?

Official labeling mentions that symptoms such as dizziness and a tingling sensation (paresthesia) may occur following the cessation of treatment, which are known as discontinuation adverse reactions. The decision regarding the discontinuation process is based on professional medical guidance and should be determined individually.


Q: Do I need a special blood test or monitoring while on Flucef?

Official documents advise that regular measurements of potassium levels are recommended during therapy, particularly when higher doses are administered. Additionally, close monitoring of blood coagulation may be necessary if the medicine is co-administered with certain blood-thinning agents.

How should Flucef be stored and disposed of?

How to Store and Dispose of Flucef (Flucloxacillin)

The storage and disposal of Flucef must strictly follow regulatory documentation to maintain product stability and safety.

Storage Conditions

Preparation Type Temperature and Environment Requirements
Capsules/Tablets Store at a temperature not exceeding 25°C. Keep in the original package, in a cool, dry place, protected from heat and dampness.
Oral Liquid (Reconstituted) Must be stored in the refrigerator, but it must not be frozen. Discard any unused mixture after 14 days.

All forms of this medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. The injectable preparation must not be mixed with blood products or other proteinaceous fluids.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flucef found in:

A-Z Index: